|
李颖.结核病短程治疗的研究现状和思考[J].内科急危重症杂志,2025,31(5):422-428
|
| DOI：10.11768/nkjwzzzz20250506 |
| 中文关键词: 结核病 临床研究 短程治疗 耐药结核 特殊人群结核 |
| 英文关键词: |
| 基金项目:国家自然科学基金面上项目（82473220） |
|
| 摘要点击次数: 17 |
| 全文下载次数: 18 |
| 中文摘要: |
| 摘要 结核病是全球发病率和死亡率较高的传染病之一。疗程是结核病患者治愈的一个关键因素。传统结核病治疗方案因疗程长、药物毒性及依从性差等问题，严重影响全球结核病防控。短程治疗，如基于莫西沙星的4个月方案获世界卫生组织推荐用于轻症敏感肺结核患者，含贝达喹啉、普托马尼等的全口服方案使耐多药肺结核（MDR-TB）的治疗缩短至6~9个月，短程治疗显著提升结核病治疗可及性及有效性，已经成为革新治疗策略的核心方向。本文系统总结结核病的短程治疗方案最新研究进展，并对目前面临的临床问题和未来研究方向进行探讨。 |
| 英文摘要: |
| Abstract Tuberculosis (TB) remains one of the infectious diseases with high global incidence and mortality rates.Treatment duration is a critical factor in achieving cure for TB patients. Conventional TB regimens plagued by extended duration, drug toxicity, and poor adherence severely imped global TB control efforts. Short-course regimens, exemplified by the World Health Organization (WHO) endorsed 4-month moxifloxacin based regimen for non-severe drug sensitive pulmonary TB, and all-oral regimens incorporating bedaquiline and pretomanid that shorten multidrug-resistant tuberculosis (MDR-TB) treatment to 6-9 months, have substantially enhanced TB treatment accessibility and effectiveness.Consequently, shortening treatment duration has emerged as a pivotal strategy in transforming TB management paradigms. This article systematically reviews recent advances in short-course TB regimens and discusses current clinical challenges and future research directions. |
|
